The dynamic interplay between cardiac inflammation and fibrosis

TP Thomas, LA Grisanti - Frontiers in physiology, 2020 - frontiersin.org
Heart failure is a leading cause of death worldwide. While there are multiple etiologies
contributing to the development of heart failure, all cause result in impairments in cardiac …

[HTML][HTML] Lipid oxidation in pathophysiology of atherosclerosis: Current understanding and therapeutic strategies

R Salekeen, AN Haider, F Akhter, MM Billah… - International Journal of …, 2022 - Elsevier
A marked increase in the global prevalence of ischemic heart disease demands focused
research for novel and more effective therapeutic strategies. At present, atherosclerotic …

Microtubules increase diastolic stiffness in failing human cardiomyocytes and myocardium

MA Caporizzo, CY Chen, K Bedi, KB Margulies… - Circulation, 2020 - Am Heart Assoc
Background: Diastolic dysfunction is a prevalent and therapeutically intractable feature of
heart failure (HF). Increasing ventricular compliance can improve diastolic performance, but …

Cardiogenic shock: incidence, survival and mechanical circulatory support usage 2007–2017-insights from a national registry

CN Lang, K Kaier, V Zotzmann, P Stachon… - Clinical Research in …, 2021 - Springer
Background A central element in the management of cardiogenic shock (CS) comprises
mechanical circulatory support (MCS) systems to maintain cardiac output (CO). This study …

Modern trends in diuretics development

T Titko, L Perekhoda, I Drapak, Y Tsapko - European Journal of Medicinal …, 2020 - Elsevier
Diuretics are the first-line therapy for widespread cardiovascular and non-cardiovascular
diseases. Traditional diuretics are commonly prescribed for treatment in patients with …

Advances in 3D organoid models for stem cell-based cardiac regeneration

M Martin, EKN Gähwiler, M Generali… - International Journal of …, 2023 - mdpi.com
The adult human heart cannot regain complete cardiac function following tissue injury,
making cardiac regeneration a current clinical unmet need. There are a number of clinical …

Mitigation of cardiovascular disease and toxicity through NRF2 signalling

JA Roberts, RD Rainbow, P Sharma - International journal of molecular …, 2023 - mdpi.com
Cardiovascular toxicity and diseases are phenomena that have a vastly detrimental impact
on morbidity and mortality. The pathophysiology driving the development of these conditions …

Improving mitochondrial function in preclinical models of heart failure: therapeutic targets for future clinical therapies?

A Gorący, J Rosik, J Szostak, B Szostak… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Heart failure is a complex clinical syndrome resulting from the unsuccessful
compensation of symptoms of myocardial damage. Mitochondrial dysfunction is a process …

Metformin and heart failure–related outcomes in patients with or without diabetes: A systematic review of randomized controlled trials

PV Dludla, TM Nyambuya, R Johnson, S Silvestri… - Heart Failure …, 2021 - Springer
Metformin is considered a safe anti-hyperglycemic drug for patients with type 2 diabetes
(T2D); however, information on its impact on heart failure–related outcomes remains …

Days alive out of hospital in heart failure: insights from the PARADIGM-HF and CHARM trials

Y Chen, J Lawrence, N Stockbridge - American Heart Journal, 2021 - Elsevier
Background An endpoint that has received some attention in recent cardiovascular trials is
'days alive and out of hospital'(DAOH). Percent DAOH is a natural extension of DAOH that …